Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus

Lupus

Volumn 6, Issue 4, 1997, Pages 415-417

  De Pita O ^a   Bellucci, A M ^a   Ruffelli, M ^a   Girardelli, C R ^a   Puddu, P ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ADULT; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LETTER; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; COMPLEMENT C3; DNA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; SKIN; TREATMENT FAILURE;

EID: 0030919040     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339700600414     Document Type: Article

References (7)

1. Schwartz SA. Intravenous immunoglobulin (IVIG) for therapy of autoimmune disorders. J Clin Immunol 1990; 112: 278-280.
2. Foley-Nolan D, Gooi HC. Current rheumatological uses of intravenous immunoglobulin. Br J Rheumatol 1994; 33: 1002-1006.
3. Cherin P et al. Efficacy of intravenous gammaglobulin therapy in chronic refractary polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91: 162-168.
4. Collet E et al. Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br J Dermatol 1994; 130: 231-234.
5. Messer G et al. High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris. BrJ Dermatol 1995; 133: 10141015.
6. Francioni C et al. Long term IVIG treatment in Systemic Lupus Erythematosus. Clin Ex Rheumatol 1994; 12: 163-168.
7. Lin CY, Hsu HC, Chan H. Improvement of histological and immunological change in steroid and immunosuppressive drugresistant lupus nephritis by high-dose intravenous gammaglobulin. Nephron 1989; 53: 303-310.